Compare
TScan Therapeutics, Inc. vs Alector, Inc. vs X4 Pharmaceuticals, Inc vs Editas Medicine, Inc.
| Latest fiscal year | TScan Therapeutics, Inc. TCRX | Alector, Inc. ALEC | X4 Pharmaceuticals, Inc XFOR | Editas Medicine, Inc. EDIT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.32M | $21.05M | $35.11M | $40.52M |
| Revenue growth (YoY) | +266.7% | -79.1% | n/m | +25.4% |
| Gross margin | n/a | n/a | 83.6% (computed) | n/a |
| Operating margin | n/m | -741.3% | -247.4% | -394.9% |
| Net margin | n/m | -679.2% | -225.6% | -395.0% |
| Net income | -$129.77M | -$142.93M | -$79.20M | -$160.06M |
| EPS (Diluted) | -$1.00 | -$1.39 | -$1.87 | -$1.80 |
| Operating cash flow | -$135.32M | -$184.03M | -$85.62M | -$165.24M |
| Free cash flow | -$139.73M | -$184.07M | -$85.62M | -$165.85M |
| Cash & equivalents | $152.41M | $65.80M | $217.05M | $146.65M |
| Total assets | $228.79M | $293.24M | $290.46M | $186.53M |
| Total liabilities | $105.67M | $262.59M | $104.17M | $159.25M |
| Shareholders' equity | $123.12M | $30.65M | $186.29M | $27.29M |
| Return on year-end equity | -105.4% | -466.3% | -42.5% | -586.6% |
| Shares outstanding | n/a | 110.36M | 90.91M | 97.87M |
Revenue, most recent five fiscal years
| Fiscal year | TScan Therapeutics, Inc. | Alector, Inc. | X4 Pharmaceuticals, Inc | Editas Medicine, Inc. |
|---|---|---|---|---|
| Latest | $10.32M Ended 2025-12-31 | $21.05M Ended 2025-12-31 | $35.11M Ended 2025-12-31 | $40.52M Ended 2025-12-31 |
| 1 year earlier | $2.82M Ended 2024-12-31 | $100.56M Ended 2024-12-31 | $2.56M Ended 2024-12-31 | $32.31M Ended 2024-12-31 |
| 2 years earlier | $21.05M Ended 2023-12-31 | $97.06M Ended 2023-12-31 | $0 Ended 2023-12-31 | $78.12M Ended 2023-12-31 |
| 3 years earlier | $13.54M Ended 2022-12-31 | $133.62M Ended 2022-12-31 | $0 Ended 2022-12-31 | $19.71M Ended 2022-12-31 |
| 4 years earlier | $10.14M Ended 2021-12-31 | $207.09M Ended 2021-12-31 | $0 Ended 2021-12-31 | $25.54M Ended 2021-12-31 |